Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders

被引：0
|
作者：
Lehmann-Horn, K. [1 ]
Schleich, E. [1 ]
Hertzenberg, D. [1 ]
Hapfelmeier, A. [1 ]
Kuempfel, T. [1 ]
von Bubnhoff, N. [1 ]
Hohlfeld, R. [1 ]
Berthele, A. [1 ]
Hemmer, B. [1 ]
Weber, M. S. [1 ]
机构：
[1] Tech Univ Munich, D-80290 Munich, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1122
引用
收藏
页码：S519 / S519
页数：1
相关论文
共 50 条
  • [41] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    Eisenberg, R
    Albert, D
    Stansberry, J
    Tsai, D
    Kolasinski, S
    Khan, S
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S9 - S10
  • [42] Anti-CD20 monoclonal antibody as a new treatment modality for B-cell lymphoma
    Hotta, T
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 2002, 35 (04) : 275 - 279
  • [43] New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
    Robak, Tadeusz
    Robak, Ewa
    BIODRUGS, 2011, 25 (01) : 13 - 25
  • [44] New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
    Tadeusz Robak
    Ewa Robak
    BioDrugs, 2011, 25 : 13 - 25
  • [45] The effect of B-cell depletion with an anti-CD20 antibody on the immunoglobulin heavy-chain repertoire in a patient with rheumatoid arthritis
    Rouziere, A-S
    Kneitz, C.
    Doerner, T.
    Tony, H-P
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 : S46 - S46
  • [46] Ofatumumab is a fully human anti-CD20 antibody achieving potent B-cell depletion through binding a distinct epitope
    Smith, P.
    Kakarieka, A.
    Wallstroem, E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 592 - 592
  • [47] The effect of B-cell depletion with an anti-CD20 antibody on the immunoglobulin heavy-chain repertoire in a patient with rheumatoid arthritis
    A-S Rouzière
    C Kneitz
    T Dörner
    H-P Tony
    Arthritis Research & Therapy, 7
  • [48] Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?
    Ysebaert, Loic
    Klein, Christian
    Quillet-Mary, Anne
    BLOOD, 2014, 124 (21)
  • [49] Targeted B-cell depletion using rituximab (anti-CD20) in recalcitrant autoimmune urticaria: Efficacy, safety, and mechanisms of action
    Bingham, C. O., III
    Jones, P. E.
    Gober, L. M.
    Eckman, J. A.
    Sterba, P. M.
    Saini, S. S.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S172 - S172
  • [50] Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis
    Fox, E.
    Steinman, L.
    Hartung, H.
    Alvarez, E.
    Qian, P.
    Wray, S.
    Robertson, D.
    Huang, D.
    Selmaj, K.
    Wynn, D.
    Weiss, M. S.
    Bosco, J. A.
    Power, S. A.
    Mok, K. A.
    Lee, L.
    Cree, B. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 68 - 68
12345